Balázs Halmos

29.6k total citations · 5 hit papers
280 papers, 12.7k citations indexed

About

Balázs Halmos is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Balázs Halmos has authored 280 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Pulmonary and Respiratory Medicine, 179 papers in Oncology and 74 papers in Molecular Biology. Recurrent topics in Balázs Halmos's work include Lung Cancer Treatments and Mutations (148 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Lung Cancer Diagnosis and Treatment (45 papers). Balázs Halmos is often cited by papers focused on Lung Cancer Treatments and Mutations (148 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Lung Cancer Diagnosis and Treatment (45 papers). Balázs Halmos collaborates with scholars based in United States, Germany and Italy. Balázs Halmos's co-authors include Daniel G. Tenen, Susumu Kobayashi, Titus J. Boggon, Pasi A. Jänne, Matthew Meyerson, Bruce E. Johnson, Olivier Kocher, Tajhal Dayaram, Michael J. Eck and Lecia V. Sequist and has published in prestigious journals such as New England Journal of Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Balázs Halmos

256 papers receiving 12.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 3.2k citations Susumu Kobayashi, Titus J. Boggon et al. profile →
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

2012 976 citations Balázs Halmos, Lecia V. Sequist et al. profile →
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

2020 521 citations Vikas Mehta, Sanjay Goel et al. Cancer Discovery profile →
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

2020 409 citations Luis Paz‐Ares, Ying Cheng et al. Journal of Thoracic Oncology profile →
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

2023 233 citations Ying Cheng, Balázs Halmos et al. profile →

Peers

Countries citing papers authored by Balázs Halmos

Since Specialization

Citations

This map shows the geographic impact of Balázs Halmos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Balázs Halmos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Balázs Halmos more than expected).

Fields of papers citing papers by Balázs Halmos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Balázs Halmos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Balázs Halmos. The network helps show where Balázs Halmos may publish in the future.

Co-authorship network of co-authors of Balázs Halmos

This figure shows the co-authorship network connecting the top 25 collaborators of Balázs Halmos. A scholar is included among the top collaborators of Balázs Halmos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Balázs Halmos. Balázs Halmos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast 2025 ·Oncology and Therapy ·Balázs Halmos, (unknown), (unknown), Wade T. Iams, Xiuning Le, (unknown), (unknown), Luis E. Raez, Jonathan W. Riess, Joshua K. Sabari, (unknown), (unknown), Yichuan Xia, (unknown), Denise D’Andrea, (unknown), Andrew L. Johnson, Melissa L. Johnson	0
2	Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT) 2025 ·International Journal of Radiation OncologyBiologyPhysics ·Nitin Ohri, William Bodner, Rafi Kabarriti, V. Shankar, Rasim Gucalp, Haiying Cheng, Balázs Halmos	1
3	Calls to action on lung cancer management and research 2024 ·The Oncologist ·(unknown), Fred R. Hirsch, Paul A. Bunn, Peter Ujházy, (unknown), Christine D. Berg, David P. Carbone, Balázs Halmos, Harpreet Singh, Hossein Borghaei, Andrea Ferris, Corey J. Langer, Sanja Đačić, Tony Mok, Solange Peters, Bruce E. Johnson	1
4	Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up 2024 ·Journal of Thoracic Oncology ·Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino, Takayasu Kurata, Ying Cheng, Erin Jensen, (unknown), (unknown), Luis Paz‐Ares	19
5	Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors 2024 ·The Oncologist ·(unknown), (unknown), Asaad Trabolsi, Estelamari Rodríguez, (unknown), Jennifer R. Ribeiro, (unknown), Emmanuel S. Antonarakis, Emil Lou, Misako Nagasaka, (unknown), Heinz‐Josef Lenz, Stephen V. Liu, Balázs Halmos, Dave S.�B. Hoon, Peter A. Seeber, C. Patrick, Wafik S. El‐Deiry, Ari M. Vanderwalde, Gilberto Lopes	7
6	Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways 2023 ·Cancers ·(unknown), (unknown), Lei Deng, (unknown), (unknown), Christopher Su, (unknown), Xingxing Zang, Balázs Halmos, Alain Borczuk, Haiying Cheng	11
7	Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants 2023 ·JCO Precision Oncology ·(unknown), So Yeon Kim, (unknown), (unknown), K.H. Ramesh, (unknown), Paul K. Paik, Balázs Halmos	0
8	Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy 2022 ·Clinical Lung Cancer ·T.Y. Andraos, Balázs Halmos, Haiying Cheng, Calvin Huntzinger, Shervin M. Shirvani, Nitin Ohri	5
9	Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer 2022 ·Scientific Reports ·Kunal Chaudhary, Connor J. Kinslow, Haiying Cheng, José M. Silva, Jiyang Yu, Tony J. C. Wang, Tom K. Hei, Balázs Halmos, Simon K. Cheng	10
10	Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System breakdown → 2020 ·Cancer Discovery ·Vikas Mehta, Sanjay Goel, Rafi Kabarriti, Daniel J. Cole, Mendel Goldfinger, Ana Acuña-Villaorduña, Kith Pradhan, Raja Thota, Stan Reissman, Joseph A. Sparano, Benjamin A. Gartrell, Richard V. Smith, Nitin Ohri, Madhur Garg, Andrew D. Racine, Shalom Kalnicki, Román Pérez-Soler, Balázs Halmos, Amit Verma	521
11	Daily Step Counts Predict Outcomes for Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Nitin Ohri, Balázs Halmos, William Bodner, Haiying Cheng, Chandan Guha, Shalom Kalnicki, (unknown)	1
12	MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors 2017 ·Clinical Cancer Research ·Matthew A. Smith, (unknown), (unknown), (unknown), Hans‐Ulrich Schildhaus, Vincent Vuaroqueaux, Balázs Halmos, Alain Borczuk, Y. Ann Chen, Ben Creelan, Theresa A. Boyle, Eric B. Haura	11
13	Update in Lung Cancer 2014 2015 ·American Journal of Respiratory and Critical Care Medicine ·Avrum Spira, Balázs Halmos, Charles A. Powell	31
14	MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents 2011 ·Cancer Research ·Weiwen Fan, Zhe Tang, Lihong Yin, Bei Morrison, (unknown), Pingfu Fu, Honglian Huang, (unknown), Shan Jiang, Adam Kresak, Scott J. Howell, Amit Vasanji, Chris A. Flask, Balázs Halmos, Henry Koon, C. Patrick	59
15	15-Hydroxyprostaglandin Dehydrogenase is a Target of Hepatocyte Nuclear Factor 3β and a Tumor Suppressor in Lung Cancer 2008 ·Cancer Research ·Guosheng Huang, Rosana Eisenberg, Min Yan, Stefano Monti, Earl Lawrence, Pingfu Fu, (unknown), Ester Löwenberg, Todd R. Golub, Jaime R. Merchan, Daniel G. Tenen, Sanford D. Markowitz, Balázs Halmos	36
16	Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies 2007 ·Cancer Research ·Zhiwei Yu, Titus J. Boggon, Susumu Kobayashi, (unknown), C. Patrick, Afshin Dowlati, Jeffrey A. Kern, Daniel G. Tenen, Balázs Halmos	57
17	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling 2006 ·Cancer Research ·Susumu Kobayashi, Takeshi Shimamura, Stefano Monti, Ulrich Steidl, Christopher J. Hetherington, April M. Lowell, Todd R. Golub, Matthew Meyerson, Daniel G. Tenen, Geoffrey I. Shapiro, Balázs Halmos	98
18	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib 2006 ·Clinical Cancer Research ·David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal I. Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balázs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne	491
19	Gefitinib resistance caused by a secondary mutation of the epidermal growth factor receptor 2005 ·Cancer Research ·Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos	0
20	A Transcriptional Profiling Study of CCAAT/Enhancer Binding Protein Targets Identifies Hepatocyte Nuclear Factor 3β as a Novel Tumor Suppressor in Lung Cancer 2004 ·Cancer Research ·Balázs Halmos, Daniela S. Daniela Sanchez Bassères, Stefano Monti, (unknown), Tajhal Dayaram, Katalin Ferenczi, Bas J. Wouters, Claudia S. Huettner, Todd R. Golub, Daniel G. Tenen	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact